BioConst生物常量

BioConst

Bone Condition Atlas

Research Note: Bone Condition Atlas

Published June 2026

Bone conditions are easier to understand when they are grouped by what fails: mineralization, remodeling, collagen, blood supply, kidney-mineral control, infection, or malignant invasion. This atlas maps major bone-condition families by pathology, current clinical strategy classes, and research-stage directions.

This is a research map, not medical advice. It does not diagnose, rank personal risk, recommend screening, recommend supplements, or recommend starting or stopping any treatment.

How to Read This Atlas

Each condition family is written in the same frame:

  • Pathology: what is failing in the bone system.
  • Current clinical strategy classes: broad categories clinicians may use in care, depending on diagnosis and context.
  • Research-stage directions: approaches being studied or refined, not public-use recommendations.
  • Boundary: what BioConst will not infer from the category.

The map is broad, not exhaustive. It covers the major families that matter for bone strength, bone quality, skeletal growth, fracture resistance, and systemic bone involvement.

1. Osteoporosis and Fragility Fracture

  • Pathology: bone mass and bone quality decline until ordinary stress or a low-trauma fall can produce fracture. NIAMS describes osteoporosis as a disease that weakens bones and raises fracture risk. Source: NIAMS osteoporosis.
  • Current clinical strategy classes: fracture-risk assessment, DXA-based BMD interpretation, calcium and vitamin D sufficiency when clinically relevant, weight-bearing and muscle-strengthening activity, fall-risk reduction, and prescription drug classes such as antiresorptive or bone-forming medicines when indicated. Source: NIAMS osteoporosis treatment steps.
  • Research-stage directions: better fracture-endpoint trials, better therapy sequencing, better fall-prevention integration, and biomarkers that separate mineral density change from fracture-resistance change.
  • Boundary: BioConst does not turn a T-score, supplement habit, or age bracket into personal advice.

2. Low Bone Mass / Osteopenia

  • Pathology: BMD is below the young-adult reference range but not in the osteoporosis range. NIAMS lists T-score ranges used for normal bone density, low bone density, and osteoporosis in postmenopausal women and men age 50 or older. Source: NIAMS BMD tests.
  • Current clinical strategy classes: risk integration rather than label-only management: age, fracture history, falls, medications, family history, and BMD can all matter. FRAX exists because BMD alone is not enough to identify all high-risk people. Source: Sheffield FRAX overview.
  • Research-stage directions: improved risk models that combine BMD, fall history, bone turnover, imaging, and frailty measures.
  • Boundary: low bone mass is not a self-treatment instruction.

3. Osteomalacia and Rickets

  • Pathology: bone matrix is present but mineralization is defective. Rickets occurs in children with growing bones; osteomalacia is the adult soft-bone counterpart. MedlinePlus describes rickets as softening and weakening of bones in children, usually because of prolonged vitamin D deficiency. Source: MedlinePlus rickets.
  • Current clinical strategy classes: identify and correct the cause of defective mineralization, which can involve vitamin D, calcium, phosphate, malabsorption, kidney disease, liver disease, or inherited phosphate handling. Source: NCBI Bookshelf, osteomalacia.
  • Research-stage directions: better diagnosis of genetic phosphate-wasting disorders, pathway-specific therapies for rare mineralization disorders, and cleaner separation of deficiency correction from routine supplement marketing.
  • Boundary: "vitamin D matters" is not the same claim as "routine supplementation prevents fractures in everyone."

4. CKD-Mineral and Bone Disorder / Renal Osteodystrophy

  • Pathology: chronic kidney disease can disturb phosphate, calcium, parathyroid hormone, vitamin D metabolism, bone turnover, mineralization, and vascular calcification. NIDDK describes mineral and bone disorder in CKD as a problem that affects bones, heart, and blood vessels. Source: NIDDK mineral and bone disorder in CKD.
  • Current clinical strategy classes: CKD-MBD care works through kidney-specific monitoring and management of phosphate, calcium, PTH, vitamin D status, diet, binders, vitamin D analogs, calcimimetics, dialysis context, and sometimes parathyroid surgery. KDIGO guidelines frame treatment around serial assessments rather than single lab values. Source: KDIGO CKD-MBD guideline update.
  • Research-stage directions: better bone-turnover classification without invasive biopsy, better endpoints linking mineral markers to fractures and cardiovascular outcomes, and better tailoring across dialysis and non-dialysis populations.
  • Boundary: BioConst will not map CKD lab values into public treatment instructions.

5. Hyperparathyroid Bone Disease

  • Pathology: excess parathyroid hormone can increase bone turnover and bone loss, with different contexts in primary, secondary, and tertiary hyperparathyroidism. NIDDK describes primary hyperparathyroidism as overactive parathyroid glands causing too much PTH and high blood calcium. Source: NIDDK primary hyperparathyroidism.
  • Current clinical strategy classes: diagnosis of cause, calcium/PTH/vitamin D assessment, kidney and bone evaluation, monitoring, surgery in selected primary cases, and context-specific medical management.
  • Research-stage directions: better prediction of skeletal benefit after intervention, better management of normocalcemic and kidney-related variants, and stronger outcome data for bone quality rather than lab normalization alone.
  • Boundary: calcium, PTH, and vitamin D values require clinical context; they are not public self-management targets.

6. Paget Disease of Bone

  • Pathology: focal bone remodeling becomes excessive and disorganized, producing enlarged but structurally abnormal bone. NIAMS describes Paget disease as a disorder in which bone breaks down and regrows abnormally. Source: NIAMS Paget disease.
  • Current clinical strategy classes: diagnosis with imaging and alkaline phosphatase context, pain and complication management, bisphosphonate therapy in appropriate cases, and orthopedic care for fracture, deformity, or joint complications. Source: NIAMS Paget treatment steps.
  • Research-stage directions: genetic susceptibility mapping, better predictors of complication risk, and improved monitoring of focal skeletal activity.
  • Boundary: high remodeling markers do not mean the same thing across Paget disease, CKD-MBD, osteoporosis, and malignancy.

7. Osteogenesis Imperfecta and Heritable Fragility

  • Pathology: inherited defects, often involving type I collagen biology, make bone fragile and fracture-prone. NIAMS describes osteogenesis imperfecta as a genetic disorder causing bones to break easily. Source: NIAMS osteogenesis imperfecta.
  • Current clinical strategy classes: multidisciplinary fracture care, physical therapy, mobility support, orthopedic surgery when needed, hearing/dental monitoring in relevant types, and medicines used in specialist contexts to improve bone strength or reduce fracture burden.
  • Research-stage directions: genotype-specific classification, anabolic or pathway-targeted medicines, cell and gene-therapy research, and better registries that measure mobility, pain, fractures, and quality of life.
  • Boundary: inherited bone fragility cannot be reduced to calcium intake or BMD alone.

8. Osteopetrosis / High-Density Brittle Bone

  • Pathology: bone resorption fails, often because osteoclasts do not form or function normally. Bone can become dense but brittle, and marrow space can be compromised. MedlinePlus Genetics describes osteopetrosis as a disorder in which bone becomes abnormally compact and dense but prone to fracture. Source: MedlinePlus Genetics, osteopetrosis.
  • Current clinical strategy classes: subtype diagnosis, supportive care for fractures and compression complications, management of anemia or infection risk when marrow is affected, and hematopoietic stem-cell transplantation for selected severe osteoclast-intrinsic forms.
  • Research-stage directions: earlier genetic diagnosis, gene-corrected hematopoietic stem-cell approaches, and better separation of osteoclast-intrinsic disease from forms where transplantation will not address the cause.
  • Boundary: high bone density is not automatically strong bone.

9. Fibrous Dysplasia / Skeletal Mosaicism

  • Pathology: post-zygotic GNAS variants can replace normal bone and marrow with fibro-osseous tissue, producing lesions, deformity, pain, fracture risk, and endocrine involvement in McCune-Albright syndrome. NIDCR describes fibrous dysplasia/McCune-Albright syndrome as involving abnormal bone, skin pigmentation, and endocrine problems. Source: NIDCR FD/MAS.
  • Current clinical strategy classes: symptom and complication monitoring, imaging when clinically needed, orthopedic stabilization for deformity or fracture, endocrine management, pain management, and specialist surveillance.
  • Research-stage directions: pathway-specific studies around GNAS/cAMP signaling, lesion biology, pain mechanisms, and targeted agents such as RANKL-pathway inhibition under specialist research conditions.
  • Boundary: a focal lesion map is not a whole-body bone-health score.

10. Osteonecrosis / Avascular Necrosis

  • Pathology: bone tissue dies after blood supply is disrupted. The femoral head is a common clinically important site. AAOS describes osteonecrosis of the hip as bone death caused by impaired blood supply. Source: AAOS osteonecrosis of the hip.
  • Current clinical strategy classes: cause and stage assessment, imaging, activity modification in selected cases, pain management, core decompression or other joint-preserving surgery in some early cases, and joint replacement in advanced collapse.
  • Research-stage directions: earlier imaging biomarkers, biologic augmentation of joint-preserving procedures, cell-based repair studies, and better prediction of collapse.
  • Boundary: osteonecrosis is a vascular and structural problem, not a mineral-intake problem.

11. Osteomyelitis / Bone Infection

  • Pathology: infection reaches bone through bloodstream spread, nearby tissue, trauma, surgery, or impaired circulation. NCBI Bookshelf describes osteomyelitis as inflammation of bone caused by infection, often bacterial. Source: NCBI Bookshelf, osteomyelitis.
  • Current clinical strategy classes: organism identification when possible, antimicrobial therapy, source control, debridement or drainage when needed, hardware and wound management, and vascular/metabolic management in diabetic or ischemic contexts.
  • Research-stage directions: faster diagnostics, biofilm-disrupting strategies, local antibiotic delivery, imaging that separates infection from sterile inflammation, and host-risk stratification.
  • Boundary: bone infection is not part of the normal aging-remodeling spectrum.

12. Bone Tumors and Metastatic Bone Disease

  • Pathology: malignant cells can arise in bone or invade bone from another cancer. NCI distinguishes primary bone cancers from cancers that spread to bone from elsewhere. Source: NCI bone cancer.
  • Current clinical strategy classes: oncology diagnosis, staging, surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy in selected tumor contexts, pain control, fracture stabilization, and bone-modifying agents in some metastatic settings. Source: NCI metastatic cancer.
  • Research-stage directions: molecular classification, immunotherapy combinations, radiopharmaceuticals, tumor-microenvironment targeting, and better prediction of skeletal-related events.
  • Boundary: cancer-related bone loss and age-related osteoporosis can interact, but they are not the same disease category.

13. Myeloma Bone Disease

  • Pathology: plasma-cell malignancy in marrow can drive osteolytic lesions by increasing osteoclast activity and suppressing osteoblast activity. NCI describes multiple myeloma as cancer that forms in plasma cells and can damage bones. Source: NCI multiple myeloma.
  • Current clinical strategy classes: anti-myeloma systemic therapy, imaging-based bone assessment, bone-modifying agents in indicated contexts, pain control, radiation for selected lesions, and orthopedic or spine procedures when instability or compression requires specialist care.
  • Research-stage directions: immune therapies, microenvironment-targeted strategies, better bone-repair endpoints, and agents aimed at restoring formation as well as reducing resorption.
  • Boundary: a myeloma bone lesion is not comparable to a nutrition-related low-BMD state.

Cross-Cutting Mechanisms

Across these families, bone can fail through different mechanisms:

  • Too little mineral deposited into matrix.
  • Too much resorption relative to formation.
  • Disorganized remodeling.
  • Weak collagen or inherited matrix defects.
  • Kidney-mineral hormone disruption.
  • Blood-supply failure.
  • Infection and biofilm.
  • Malignant invasion of marrow or bone.
  • Muscle, balance, and falls converting fragility into fracture.

BioConst treats those mechanisms as separate measurement problems. The endpoint should be named before the claim is evaluated.

Current Strategy vs Research-Stage Direction

Current clinical strategies are used inside diagnosis-specific care. They may include monitoring, surgery, rehabilitation, nutrition correction, antimicrobial therapy, oncology therapy, antiresorptive medicine, anabolic medicine, or fall-risk reduction depending on the condition.

Research-stage directions ask a different question: what mechanism is being tested, in which population, against which endpoint, and for how long? A lab marker, imaging change, pain score, fall count, BMD change, fracture endpoint, and survival endpoint are not interchangeable.

Tracker Rule

BioConst will tag bone-condition claims by condition family, pathology mechanism, endpoint, population, and claim boundary. A claim about "bone health" is too vague until it says which bone disease family, which failure mode, and which measured endpoint it is talking about.